Supernus Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Rockville, Maryland, focused on developing and commercializing products for the treatment of central nervous system disorders, particularly epilepsy and ADHD. The company was founded in 2005 as a spin-off from Noven Pharmaceuticals.
Overview
flowchart TD
companies_supernus_pharmaceuti["Supernus Pharmaceuticals"]
companies_supernus_pharmaceuti["biopharmaceutical"]
companies_supernus_pharmaceuti -->|"related to"| companies_supernus_pharmaceuti
style companies_supernus_pharmaceuti fill:#81c784,stroke:#333,color:#000
companies_supernus_pharmaceuti["company"]
companies_supernus_pharmaceuti -->|"related to"| companies_supernus_pharmaceuti
style companies_supernus_pharmaceuti fill:#81c784,stroke:#333,color:#000
companies_supernus_pharmaceuti["headquartered"]
companies_supernus_pharmaceuti -->|"related to"| companies_supernus_pharmaceuti
style companies_supernus_pharmaceuti fill:#81c784,stroke:#333,color:#000
companies_supernus_pharmaceuti["Rockville"]
companies_supernus_pharmaceuti -->|"related to"| companies_supernus_pharmaceuti
style companies_supernus_pharmaceuti fill:#81c784,stroke:#333,color:#000
style companies_supernus_pharmaceuti fill:#4fc3f7,stroke:#333,color:#000
...Supernus Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Rockville, Maryland, focused on developing and commercializing products for the treatment of central nervous system disorders, particularly epilepsy and ADHD. The company was founded in 2005 as a spin-off from Noven Pharmaceuticals.
Overview
Mermaid diagram (expand to render)
Supernus has built a portfolio of approved products for epilepsy and ADHD, and is expanding into movement disorders and other CNS conditions. The company's strategy focuses on developing differentiated products with improved efficacy and safety profiles compared to existing treatments["@corporate"].
Funding
- IPO: 2012 (NASDAQ: SUPN)
- Market Cap: ~$6B (2026)
Corporate Highlights
- Founded: 2005
- Headquarters: Rockville, Maryland
- NASDAQ: SUPN
- Employees: Approximately 700
History and Development
Founding (2005)
Supernus was founded in 2005 as a spin-off from Noven Pharmaceuticals, focusing on CNS disorders with an emphasis on novel formulations of existing drugs.
Growth (2005-2020)
- 2013: FDA approval of OXTELLAR XR and TROKENDI XR for epilepsy
- 2018: Acquisition of epilepsy portfolio including EPIDIOLEX
- 2021: FDA approval of Qelbree (viloxazine) for ADHD
Recent Developments (2021-Present)
- Expanded Parkinson's disease portfolio with apomorphine products
- Advanced novel pipeline programs in depression and epilepsy
- Focus on treatment-resistant conditions
Approved Products
Epilepsy Portfolio
| Product | Active Ingredient | Indication | Approval |
|---------|------------------|------------|----------|
| OXTELLAR XR | Oxcarbazepine | Epilepsy | 2013[@oxtellar] |
| TROKENDI XR | Topiramate | Epilepsy | 2013[@trokendi] |
| EPIDIOLEX | Cannabidiol | Rare epilepsies | 2018 |
OXTELLAR XR and TROKENDI XR are extended-release formulations of generic epilepsy drugs, designed to provide improved seizure control with once-daily dosing and more stable blood levels.
Parkinson's Disease
| Product | Indication | Mechanism |
|---------|------------|-----------|
| APOKYN | Parkinson's OFF episodes | Dopamine agonist (injection) |
| APOMINE | Parkinson's | Dopamine agonist |
APOKYN (apomorphine injection) provides rapid rescue from OFF episodes in Parkinson's disease patients.
Autonomic Dysfunction in Parkinson's Disease
Supernus's Parkinson's disease products address autonomic dysfunction manifestations:
Apomorphine Therapy and Autonomic Function
APOKYN and the SPN-830 continuous infusion address several autonomic aspects of PD:
- OFF-Time Reduction: Reducing "off" episodes decreases catecholamine surges that can exacerbate orthostatic hypotension
- Blood Pressure Stability: Stable dopaminergic stimulation reduces the blood pressure fluctuations seen with oral medication cycling
- GI Symptoms: Reduced OFF episodes may decrease gastroparesis symptoms and improve nutrient absorption
SPN-830 (Continuous Apomorphine Infusion)The Phase 3 apomorphine infusion program offers particular benefits for autonomic function:
- Continuous Delivery: Maintains stable plasma drug levels, avoiding peaks and troughs that trigger autonomic symptoms
- Sleep Quality: Overnight continuous delivery may reduce nocturnal motor symptoms that disrupt sleep architecture
- Orthostatic Hypotension Management: Stable dopamine levels reduce the risk of medication-induced blood pressure drops
Qelbree (Viloxazine) - Norepinephrine ModulationWhile approved for ADHD, viloxazine's norepinephrine reuptake inhibition has potential applications:
- Autonomic Regulation: Norepinephrine plays a key role in blood pressure regulation through the [sympathetic nervous system](/entities/autonomic-nervous-system)
- Research Interest: Investigated for autonomic symptoms in PD and related disorders
ADHD Portfolio
| Product | Indication | Mechanism |
|---------|------------|-----------|
| MYDAYIS | ADHD (13+) | Mixed amphetamine salts (extended-release) |
| Qelbree | ADHD (6-17) | Selective norepinephrine reuptake inhibitor |
| Vivalan | ADHD | Guanfacine extended-release |
Qelbree (Viloxazine): Approved in 2021, Qelbree represents the first non-stimulant ADHD medication approved in over 20 years[@qelbree].
Pipeline Programs
Clinical Development
| Drug Candidate | Indication | Mechanism | Stage |
|---------------|------------|-----------|-------|
| SPN-820 | Treatment-resistant depression | AMPA modulator | Phase 2[@spn] |
| SPN-817 | Epilepsy | Novel mechanism | Phase 1 |
| SPN-830 | Parkinson's disease | Apomorphine infusion | Phase 3 |
Science and Technology
Extended-Release Technology
Supernus's products leverage extended-release technology to improve patient outcomes:
- Once-daily dosing improves adherence
- More stable blood levels reduce side effects
- Fewer breakthrough seizures in epilepsy
AMPA Receptor Modulation
SPN-820 targets AMPA receptors for treatment-resistant depression:
- Different from SSRI/SNRI mechanisms
- May offer rapid-acting effects similar to ketamine
- Without dissociative side effects
- Novel mechanism for patients who fail multiple antidepressants[@ampa]
Neurological Relevance
Supernus addresses significant unmet needs in CNS disorders[@supernusa]:
Treatment-Resistant Depression
SPN-820 is a novel AMPA receptor modulator with potential for:
- Rapid-acting antidepressant effects (similar to ketamine)
- Without the psychotomimetic side effects of ketamine
- Oral bioavailability
- Potential for sustained response
AMPA receptor modulation represents a novel mechanism beyond current SSRIs/SNRIs and [NMDA receptor](/entities/nmda-receptor) antagonists.
Parkinson's Disease OFF Episodes
Despite dopaminergic therapy, Parkinson's patients experience OFF episodes when medication wears off:
- SPN-830 (continuous apomorphine infusion) provides steady dopamine agonist delivery
- Reduces motor fluctuations
- Improves quality of life
- Continuous subcutaneous infusion maintains stable plasma levels
Epilepsy
Extended-release formulations improve patient outcomes:
- Better medication adherence (once-daily)
- More stable drug levels (fewer breakthrough seizures)
- Reduced side effects
ADHD Non-Stimulant Option
Qelbree provides an alternative for patients who:
- Cannot tolerate stimulant side effects
- Have history of substance abuse
- Have cardiovascular concerns
- Are younger children (6-17 years old)
Financial Highlights (2024)
- Revenue: Approximately $700 million USD
- Market Cap: Approximately $2 billion USD
- R&D Investment: Approximately $150 million USD
- Focus: CNS specialty products
Related Pages
- [Epilepsy](/diseases/epilepsy)
- [Attention Deficit Hyperactivity Disorder](/diseases/attention-deficit-hyperactivity-disorder)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Treatment-Resistant Depression](/diseases/treatment-resistant-depression)
- [Dopamine Signaling](/mechanisms/dopamine-signaling)
- [GABA Signaling](/mechanisms/gaba-signaling)
- [AMPA Signaling](/mechanisms/ampa-signaling)
- [Norepinephrine Signaling](/mechanisms/norepinephrine-signaling)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Dopamine Signaling](/mechanisms/dopamine-signaling)
- [Norepinephrine Signaling](/mechanisms/norepinephrine-signaling)
- [Autonomic Nervous System](/entities/autonomic-nervous-system)
- [Apomorphine](/therapeutics/parkinsons-disease-treatment)
- [Autonomic Dysfunction in Parkinson's Disease](/diseases/autonomic-dysfunction-in-corticobasal-syndrome)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Supernus Pharmaceuticals, Company Website (n.d.)
Corporate Overview, Investor Presentation (n.d.)
OXTELLAR XR Approval, FDA (n.d.)
TROKENDI XR Approval, FDA (n.d.)
Qelbree FDA Approval, FDA Press Release (n.d.)
SPN-820 Clinical Trials, ClinicalTrials.gov (n.d.)
[AMPA Modulation in Depression, Nature Reviews Drug Discovery (n.d.)](https://doi.org/10.1038/s41573-021-00198-1)
Supernus Pipeline, Pipeline Overview (n.d.)Pathway Diagram
The following diagram shows the key molecular relationships involving Supernus Pharmaceuticals discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)